, En fonction du mis-match MIC-A

, Nous n'avons mis en évidence aucune relation entre les mis-matchs GVH/GVL, globaux et mis-matchs MIC-A 129, dans la survenue de GVH aiguë ni d'impact sur la survie, contrairement aux études de

, Cependant, les impacts d'un tel mis-match MIC-A entre le donneur et le receveur restent controversés dans la littérature

, Sur une série de 922 allogreffes, Carapito et al. montrent que les mis-matchs MIC-A sont associés à une augmentation de l'incidence de GVH aiguë grades III-IV,de GVH chronique et de la mortalité sans rechute

P. Parmar, le taux de GVH aiguë de grades II à IV est plus élevé en présence d'un mis-match MIC-A. Toutefois sa cohorte de 236 allogreffes inclue des greffes 10/10 et, vol.9

. D'autres-Études-s'opposent-À-ces-résultats and . Anderson, où il n'est mis en évidence aucune relation entre MIC-A et GVH sur des cohortes

, Cette disparité de résultats peut s'expliquer par l'absence d'homogénéité entre les populations en termes de pathologies et par la différence de taille de l'échantillon. Les données obtenues sont

, Les disparités retrouvées dans la littérature, en comparaison avec notre étude, peuvent s'expliquer par de nombreux autres critères

, Pour l'étude spécifique de l'implication des gènes MIC-A, il faut toutefois veiller à ne pas introduire de cas avec des mis-matchs HLA-B. En effet, il existe un déséquilibre de liaison entre le HLA-B de classe I et le gène MIC-A. Notre cohorte n'est composée que de patients allogreffés en compatibilité 10/10, dont 44.4% ont reçu une greffe géno-identique

, Les mis-matchs HLA-DPB1 sont, en théorie, absents dans les greffes géno-identiques mais sont présents, jusqu'à 80%, dans des greffes phéno-identiques, De plus, peu d'études intègrent la détermination HLA-DPB1 pour définir dans les allogreffes 10/10

F. Baron and R. Storb, Allogeneic Hematopoietic Cell Transplantation Following Nonmyeloablative Conditioning as Treatment for Hematologic Malignancies and Inherited Blood Disorders, Mol Ther, vol.13, issue.1, pp.26-41, 2006.

P. L. Weiden, N. Flournoy, E. D. Thomas, R. Prentice, A. Fefer et al., Antileukemic Effect of Graft-versus-Host Disease in Human Recipients of Allogeneic-Marrow Grafts, N Engl J Med, vol.300, issue.19, pp.1068-73, 1979.

L. Ruggeri, S. Parisi, E. Urbani, and A. Curti, Alloreactive Natural Killer Cells for the Treatment of Acute Myeloid Leukemia: From Stem Cell Transplantation to Adoptive Immunotherapy. Front Immunol, vol.6, 2015.

W. I. Bensinger, Recent developments in hematopoietic stem cell transplantation for multiple myeloma, Int J Hematol, vol.77, issue.3, pp.232-240, 2003.

J. M. Tiercy, How to select the best avalaible related or unrelated donor of hematopoietic stem cell? Haematol, 1016.

S. Nguyen, D. Blaise, J. Bay, P. Chevallier, N. Contentin et al., Greffes de cellules souches hématopoïétiques à partir d'un donneur haploidentique : recommandations de la SFGM-TC (deuxième partie), Pathol Biol, vol.62, issue.4, pp.185-194, 2014.

A. Sureda, P. Bader, S. Cesaro, P. Dreger, R. F. Duarte et al., Indications for allo-and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, Bone Marrow Transplant, vol.50, issue.8, pp.1037-56, 2015.

J. E. Wagner, J. N. Barker, T. E. Defor, K. S. Baker, B. R. Blazar et al., Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival, Blood, vol.100, issue.5, pp.1611-1619, 2002.

C. A. Rodrigues, V. Rocha, P. Dreger, C. Brunstein, H. Sengeloev et al., Alternative donor hematopoietic stem cell transplantation for mature lymphoid malignancies after reducedintensity conditioning regimen: similar outcomes with umbilical cord blood and unrelated donor peripheral blood, Haematologica, vol.99, issue.2, pp.370-377, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01325615

C. G. Brunstein, J. A. Gutman, D. J. Weisdorf, A. E. Woolfrey, T. E. Defor et al., Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood, Blood, vol.116, issue.22, pp.4693-4702, 2010.

J. N. Barker, D. J. Weisdorf, T. E. Defor, B. R. Blazar, P. B. Mcglave et al., Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy, Blood, vol.105, issue.3, pp.1343-1350, 2005.

C. A. Rodrigues, G. Sanz, C. G. Brunstein, J. Sanz, J. E. Wagner et al., Analysis of risk factors for outcomes after unrelated cord blood transplantation in adults with lymphoid malignancies: a study by the Eurocord-Netcord and lymphoma working party of the European group for blood and marrow transplantation, J Clin Oncol Off J Am Soc Clin Oncol, vol.27, issue.2, pp.256-63, 2009.

M. L. Macmillan, D. J. Weisdorf, C. G. Brunstein, Q. Cao, T. E. Defor et al., Acute graftversus-host disease after unrelated donor umbilical cord blood transplantation: analysis of risk factors, Blood, vol.113, issue.11, pp.2410-2415, 2009.

J. J. Cornelissen, W. Putten, . Van, L. F. Verdonck, T. M. et al., Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom? Blood, vol.109, pp.3658-66, 2007.

J. Koreth, R. Schlenk, K. J. Kopecky, S. Honda, J. Sierra et al., Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: a systematic review and meta-analysis of prospective clinical trials, JAMA J Am Med Assoc, vol.301, issue.22, pp.2349-61, 2009.

M. Mielcarek, P. J. Martin, W. Leisenring, M. Flowers, D. G. Maloney et al., Graftversus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation, Blood, vol.15, issue.2, pp.756-62, 2003.

M. M. ,

, Transfus Clin Biol J Soc Francaise Transfus Sang, vol.18, issue.2, pp.235-280, 2011.

Y. Akatsuka, Y. Morishima, K. Kuzushima, Y. Kodera, and T. Takahashi, Minor histocompatibility antigens as targets for immunotherapy using allogeneic immune reactions, Cancer Sci, vol.98, issue.8, pp.1139-1185, 2007.

J. Falkenburg, W. Marijt, .. F. Heemskerk, M. Willemze, and R. , Minor histocompatibility antigens as targets of graft-versus-leukemia reactions, Curr Opin Hematol, vol.9, issue.6, pp.497-502, 2002.

M. Mistrik, E. Bojtarova, L. Sopko, L. Masakova, L. Roziakova et al., Graft-versus-host disease management, Bratisl Lekárske Listy, vol.117, issue.7, pp.388-96, 2016.

A. C. Vigorito, P. V. Campregher, B. E. Storer, P. A. Carpenter, C. K. Moravec et al., Evaluation of NIH consensus criteria for classification of late acute and chronic GVHD, Blood, vol.114, issue.3, pp.702-710, 2009.

H. Takatsuka, Y. Takemoto, M. Okada, A. Sawada, T. Katsuno et al., Changes of cytokines during the course of graft-versus-host disease following bone marrow transplantation: a case report, Cytokine, vol.12, issue.8, pp.1225-1232, 2000.

H. J. Deeg, Cytokines in graft-versus-host disease and the graft-versus-leukemia reaction, Int J Hematol, vol.74, issue.1, pp.26-32, 2001.

G. R. Hill, W. Krenger, and J. L. Ferrara, The role of cytokines in acute graft-versus-host disease, Cytokines Cell Mol Ther, vol.3, issue.4, pp.257-66, 1997.

E. Gatza and S. W. Choi, Approaches for the prevention of graft-versus-host disease following hematopoietic cell transplantation, Int J Hematol Oncol, vol.4, issue.3, pp.113-139, 2015.

H. Glucksberg, R. Storb, A. Fefer, C. D. Buckner, P. E. Neiman et al., Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors, Transplantation, vol.18, issue.4, pp.295-304, 1974.

D. Przepiorka, D. Weisdorf, P. Martin, H. G. Klingemann, P. Beatty et al., Consensus Conference on Acute GVHD Grading, vol.15, pp.825-833, 1994.

W. Krenger, G. R. Hill, and J. L. Ferrara, Cytokine cascades in acute graft-versus-host disease, Transplantation, vol.64, issue.4, pp.553-561, 1997.

J. Ferrara and P. Reddy, Pathophysiology of Graft-Versus-Host Disease, Semin Hematol, vol.43, issue.1, pp.3-10, 2006.

G. Socié and J. Ritz, Current issues in chronic graft-versus-host disease, Blood, vol.124, issue.3, pp.374-84, 2014.

J. Pidala, M. Sarwal, S. Roedder, and S. J. Lee, Biologic markers of chronic graft vs. host disease. Bone Marrow Transplant, vol.49, pp.324-355, 2014.

J. Yu, B. E. Storer, K. Kushekhar, M. A. Zaid, Q. Zhang et al., Biomarker Panel for Chronic Graft-Versus-Host Disease, J Clin Oncol, vol.659615, 2016.

S. Z. Pavletic, L. M. Smith, M. R. Bishop, J. C. Lynch, S. R. Tarantolo et al., Prognostic factors of chronic graft-versus-host disease after allogeneic blood stem-cell transplantation, Am J Hematol, vol.78, issue.4, pp.265-74, 2005.

P. J. Martin, S. J. Lee, D. Przepiorka, M. M. Horowitz, J. Koreth et al., National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. The, Clinical Trial Design Working Group Report. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant, vol.21, issue.8, pp.1343-59, 2014.

Y. Linhares, S. Pavletic, and R. P. Gale, Chronic GVHD: Where are we? Where do we want to be? Will immunomodulatory drugs help? Bone Marrow Transplant, vol.48, pp.203-212, 2013.

H. J. Deeg, G. Socie, G. Schoch, M. Henry-amar, R. P. Witherspoon et al., Malignancies after marrow transplantation for aplastic anemia and fanconi anemia: a joint Seattle and Paris analysis of results in 700 patients, Blood, vol.87, issue.1, pp.386-92, 1996.

J. E. Wagner, J. S. Thompson, S. L. Carter, and N. A. Kernan, Effect of graft-versus-host disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-cell Depletion Trial): a multi-centre, randomised phase II-III trial. The Lancet, vol.366, pp.733-774, 2005.

N. J. Chao and B. J. Chen, Prophylaxis and Treatment of Acute Graft-Versus-Host Disease, vol.43, pp.32-41, 2006.

A. L. Gilman and J. Serody, Diagnosis and treatment of chronic graft-versus-host disease, Semin Hematol, vol.43, issue.1, pp.70-80, 2006.

F. Baron, M. B. Maris, B. M. Sandmaier, B. E. Storer, M. Sorror et al., Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning, J Clin Oncol Off J Am Soc Clin Oncol, vol.23, issue.9, pp.1993-2003, 2005.

F. Locatelli, D. Stefano, and P. , T-cell depletion to prevent GVHD after unrelated-donor marrow transplantation. The Lancet, vol.366, pp.692-696, 2005.

L. Ruggeri, M. Capanni, E. Urbani, K. Perruccio, W. D. Shlomchik et al., Effectiveness of Donor Natural Killer Cell Alloreactivity in Mismatched Hematopoietic Transplants, Science, vol.295, issue.5562, pp.2097-100, 2002.

M. A. Geller and J. S. Miller, Use of allogeneic NK cells for cancer immunotherapy, Immunotherapy, vol.3, issue.12, pp.1445-59, 2011.

E. Vivier, D. H. Raulet, A. Moretta, M. A. Caligiuri, L. Zitvogel et al., Innate or Adaptive Immunity? The Example of Natural Killer Cells, Science, vol.331, issue.6013, pp.44-53, 2011.
URL : https://hal.archives-ouvertes.fr/hal-00611585

T. L. Geiger and J. C. Sun, Development and maturation of natural killer cells, Curr Opin Immunol, vol.39, pp.82-91, 2016.

E. Sophie-caillat-zuckmann, G. Vivier, and . Thibaut, Lymphocytes NK( Natural Killer)

, Functions of natural killer cells : Article : Nature Immunology, 2016.

J. Yu, A. G. Freud, and M. A. Caligiuri, Location and cellular stages of NK cell development, Trends Immunol, vol.34, issue.12, 2013.

N. Dulphy, A. Chrétien, Z. Khaznadar, C. Fauriat, A. Nanbakhsh et al., Underground Adaptation to a Hostile Environment: Acute Myeloid Leukemia vs, Natural Killer Cells. Front Immunol, vol.7, 2016.

, Human natural killer cells: a unique innate immunoregulatory role for the CD56bright subset | Blood Journal, 2016.

M. A. Cooper, T. A. Fehniger, and M. A. Caligiuri, The biology of human natural killer-cell subsets, Trends Immunol, vol.22, issue.11, pp.633-673, 2001.

M. A. Cooper, Teach Your NK Cells Well. Immunity, vol.45, pp.229-260, 2016.

M. T. Orr and L. L. Lanier, Natural Killer Cell Education and Tolerance, Cell, vol.142, issue.6, pp.847-56, 2010.

H. G. Ljunggren and K. Kärre, In search of the "missing self": MHC molecules and NK cell recognition, Immunol Today, vol.11, issue.7, pp.237-281, 1990.

A. Diefenbach and D. H. Raulet, Strategies for target cell recognition by natural killer cells, Immunol Rev, vol.181, issue.1, pp.170-84, 2001.

E. O. Long, H. S. Kim, D. Liu, M. E. Peterson, and S. Rajagopalan, Controlling NK Cell Responses: Integration of Signals for Activation and Inhibition, Annu Rev Immunol, vol.31, 2013.

A. Beldi-ferchiou, Etude des mecanismes regulateurs des cellules NK : rôle de la molecule PD-1 et de la prostaglandine E2 (PGE2), 2015.

L. Ruggeri, A. Mancusi, E. Burchielli, F. Aversa, M. F. Martelli et al., Natural killer cell alloreactivity and haplo-identical hematopoietic transplantation, Cytotherapy, vol.8, issue.6, pp.554-562, 2006.

S. S. Farag, T. A. Fehniger, L. Ruggeri, A. Velardi, and M. A. Caligiuri, Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect, Blood, vol.100, issue.6, pp.1935-1982, 2002.

, NK cell regulation of T cell-mediated responses, 2016.

, DNA sequence analysis of NKG2, a family of related cDNA clones encoding type II integral membrane proteins on human natural killer cells, J Exp Med, vol.173, issue.4, pp.1017-1037, 1991.

P. Obeidy and A. F. Sharland, NKG2D and its ligands, Int J Biochem Cell Biol, vol.41, issue.12, pp.2364-2371, 2009.

T. L. Van-belle, V. Herrath, and M. G. , The role of the activating receptor NKG2D in autoimmunity, Mol Immunol, vol.47, issue.1, pp.8-11, 2009.

P. Spear, M. Wu, M. Sentman, and C. L. Sentman, NKG2D ligands as therapeutic targets. Cancer Immun, vol.13, 2013.

D. H. Raulet, S. Gasser, B. G. Gowen, W. Deng, and H. Jung, Regulation of ligands for the NKG2D activating receptor, Annu Rev Immunol, vol.31, pp.413-454, 2013.

T. Hayashi, K. Imai, Y. Morishita, I. Hayashi, Y. Kusunoki et al., Identification of the NKG2D Haplotypes Associated with Natural Cytotoxic Activity of Peripheral Blood Lymphocytes and Cancer Immunosurveillance, Cancer Res, vol.66, issue.1, pp.563-70, 2006.

V. Groh, S. Bahram, S. Bauer, A. Herman, M. Beauchamp et al., Cell stress-regulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium, Proc Natl Acad Sci, vol.93, issue.22, pp.12445-50, 1996.

L. Moretta, C. Bottino, D. Pende, R. Castriconi, M. C. Mingari et al., Surface NK receptors and their ligands on tumor cells, Semin Immunol, vol.18, issue.3, pp.151-159, 2006.

L. Perera, L. Shao, A. Patel, K. Evans, B. Meresse et al., Expression of nonclassical class I molecules by intestinal epithelial cells, Inflamm Bowel Dis, vol.13, issue.3, pp.298-307, 2007.

S. Schrambach, M. Ardizzone, V. Leymarie, J. Sibilia, and S. Bahram, In Vivo Expression Pattern of MICA and MICB and Its Relevance to Auto-Immunity and Cancer, PLoS ONE, vol.2, issue.6, 2007.

W. Y. Wang, W. Tian, F. M. Zhu, X. X. Liu, L. X. Li et al., MICB Polymorphisms and Linkage Disequilibrium with HLA-B in a Chinese Mongolian Population, Scand J Immunol, vol.83, issue.6, pp.456-62, 2016.

L. Fernández-messina, H. T. Reyburn, and M. Valés-gómez, Human NKG2D-ligands: cell biology strategies to ensure immune recognition. Front Immunol, vol.3, 2012.

N. Mizuki, H. Ando, M. Kimura, S. Ohno, S. Miyata et al., Nucleotide sequence analysis of the HLA class I region spanning the 237-kb segment around the HLA-B and -C genes, Genomics, vol.42, issue.1, pp.55-66, 1997.

W. Boukouaci, M. Busson, R. P. Latour, . De, V. Rocha et al., MICA-129 genotype, soluble MICA, and anti-MICA antibodies as biomarkers of chronic graft-versus-host disease, Blood, vol.114, issue.25, pp.5216-5240, 2009.

A. Steinle, P. Li, D. L. Morris, V. Groh, L. L. Lanier et al., Interactions of human NKG2D with its ligands MICA, MICB, and homologs of the mouse RAE-1 protein family, Immunogenetics, vol.53, issue.4, pp.279-87, 2001.

P. Li, D. L. Morris, B. E. Willcox, A. Steinle, T. Spies et al., Complex structure of the activating immunoreceptor NKG2D and its MHC class I-like ligand MICA, Nat Immunol, vol.2, issue.5, pp.443-51, 2001.

D. Fürst, G. Solgi, K. Recker, D. Mytilineos, H. Schrezenmeier et al., Sequence-based typing of major histocompatibility complex class I chain-related gene A alleles by use of exons 2-5 information, Tissue Antigens, vol.77, issue.3, pp.201-206, 2011.

N. Mizuki, M. Ota, M. Kimura, S. Ohno, H. Ando et al., Triplet repeat polymorphism in the transmembrane region of the MICA gene: A strong association of six GCT repetitions with Behçet disease, Proc Natl Acad Sci, vol.94, issue.4, pp.1298-303, 1997.

V. Durmanová, J. Tirpakova, M. Stuchlikova, I. Shawkatova, D. Kuba et al., Characterization of MICA gene polymorphism of HLA complex in the Slovak population, Ann Hum Biol, vol.38, issue.5, pp.570-576, 2011.

A. Isernhagen, D. Schilling, S. Monecke, P. Shah, L. Elsner et al., The MICA-129Met/Val dimorphism affects plasma membrane expression and shedding of the NKG2D ligand MICA, Immunogenetics, vol.68, pp.109-132, 2016.

A. Isernhagen, D. Malzahn, E. Viktorova, L. Elsner, S. Monecke et al., The MICA-129 dimorphism affects NKG2D signaling and outcome of hematopoietic stem cell transplantation, EMBO Mol Med, vol.7, issue.11, pp.1480-502, 2015.

W. Boukouaci, R. Al-daccak, N. Dulphy, L. Lauden, K. Amokrane et al., Soluble MICA-NKG2D interaction upregulates IFN-? production by activated CD3-CD56+ NK cells: potential impact on chronic graft versus host disease, Hum Immunol, vol.74, issue.12, pp.1536-1577, 2013.

L. Ruggeri, M. Capanni, A. Mancusi, F. Aversa, M. F. Martelli et al., Natural killer cells as a therapeutic tool in mismatched transplantation, Best Pract Res Clin Haematol, vol.17, issue.3, pp.427-465, 2004.

X. Gao, R. M. Single, P. Karacki, D. Marti, S. J. O'brien et al., Diversity of MICA and Linkage Disequilibrium with HLA-B in Two North American Populations, Hum Immunol, vol.67, issue.3, pp.152-160, 2006.

S. Parmar, M. Del-lima, Y. Zou, P. A. Patah, P. Liu et al., Donor-recipient mismatches in MHC class I chain-related gene A in unrelated donor transplantation lead to increased incidence of acute graft-versus-host disease, Blood, vol.114, issue.14, pp.2884-2891, 2009.

P. Tonnerre, N. Gérard, M. Chatelais, C. Poli, S. Allard et al., MICA Variant Promotes Allosensitization after Kidney Transplantation, J Am Soc Nephrol JASN, vol.24, issue.6, pp.954-66, 2013.
URL : https://hal.archives-ouvertes.fr/inserm-02165869

R. A. Pollock, V. Chandran, F. J. Pellett, A. Thavaneswaran, L. Eder et al., The functional MICA-129 polymorphism is associated with skin but not joint manifestations of psoriatic disease independently of HLA-B and HLA-C, Tissue Antigens, vol.82, issue.1, pp.43-50, 2013.

X. Zhou, J. Wang, H. Zou, M. M. Ward, M. H. Weisman et al., MICA, a gene contributing strong susceptibility to ankylosing spondylitis, Ann Rheum Dis, vol.73, issue.8, pp.1552-1559, 2014.

H. Suemizu, M. Radosavljevic, M. Kimura, S. Sadahiro, S. Yoshimura et al., A basolateral sorting motif in the MICA cytoplasmic tail, Proc Natl Acad Sci, vol.99, issue.5, pp.2971-2977, 2002.

O. Ashiru, P. Boutet, L. Fernández-messina, S. Agüera-gonzález, J. N. Skepper et al., Natural Killer Cell Cytotoxicity Is Suppressed by Exposure to the Human NKG2D Ligand MICA*008 That Is Shed by Tumor Cells in Exosomes, Cancer Res, vol.70, issue.2, pp.481-490, 2010.

E. Anderson, B. Grzywacz, H. Wang, T. Wang, M. Haagenson et al., Limited role of MHC class I chain-related gene A (MICA) typing in assessing graft-versus-host disease risk after fully human leukocyte antigen-matched unrelated donor transplantation, Blood, vol.114, issue.21, pp.4753-4757, 2009.

J. L. Espinoza, A. Takami, M. Onizuka, H. Sao, H. Akiyama et al., NKG2D gene polymorphism has a significant impact on transplant outcomes after HLA-fully-matched unrelated bone marrow transplantation for standard risk hematologic malignancies, Haematologica, vol.94, issue.10, pp.1427-1461, 2009.

R. Carapito, N. Jung, M. Kwemou, M. Untrau, S. Michel et al., Matching for the nonconventional MHC-I MICA gene significantly reduces the incidence of acute and chronic GVHD, Blood, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01362680

D. Fuerst, C. Neuchel, D. Niederwieser, D. Bunjes, M. Gramatzki et al., Matching for the MICA-129 polymorphism is beneficial in unrelated hematopoietic stem cell transplantation, Blood, vol.128, issue.26, pp.3169-76, 2016.

M. Askar, R. Sobecks, T. Wang, M. Haagenson, N. Majhail et al., MHC Class I Chain-Related Gene A (MICA) Donor-Recipient Mismatches and MICA-129 Polymorphism in Unrelated Donor Hematopoietic Cell Transplantations Has No Impact on Outcomes in Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, or Myelodysplastic Syndrome: A Center for International Blood and Marrow Transplant Research Study, Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant, vol.23, issue.3, pp.436-480, 2017.

Y. Park, J. Cheong, M. H. Park, M. S. Kim, J. S. Kim et al., Effect of major histocompatibility complex haplotype matching by C4 and MICA genotyping on acute graft versus host disease in unrelated hematopoietic stem cell transplantation, Hum Immunol, vol.77, issue.2, pp.176-83, 2016.